Result of AGM

Futura Medical PLC
19 July 2007


For immediate release                                        19 July 2007



                               Futura Medical Plc
                          ('Futura' or 'the Company')

                                 Result of AGM



Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative
products for consumer healthcare, held its Annual General Meeting yesterday
afternoon at which all resolutions were duly passed.



At the AGM, the Company's Chairman, Dr William Potter, made the following
comments: 'As we reported at the time of our preliminary results, we are moving
closer to EU regulatory approval of CSD500, which will be launched under the
Durex(R) brand by our partner SSL International plc. Regulatory approval
remains on track for Q4 of this year and we look forward to making the
transition to a revenue generating business with a recurring royalty stream.



'Also, as mentioned at the time of our preliminary results, we have been
encouraged by the level of interest from potential licensing partners in
MED2002, our OTC treatment for erectile dysfunction. Out-licensing negotiations
are continuing and we remain confident that a licensing partner will be secured
on attractive commercial terms in due course.



'We continue to make progress on our earlier-stage portfolio and in seeking new
applications for our novel drug delivery technology, DermaSys(R)¿.'



In accordance with AIM Rule 17, Futura Medical notes the transfer of ordinary
shares in the Company by the following Directors, though there has been no
material change to the total shareholdings of any of the Directors:



James H Barder, Chief Executive

1 Feb 05: Transfer of 236,997 Futura shares from paper certificate (in the name
of James Barder) into Carr Sheppards nominee account (Ferlim Nominees) for the
account of James Barder



4 Feb 05: Transfer of 250,000 Futura shares from paper certificate (in the name
of Charlotte Barder) into Carr Sheppards nominee account (Ferlim Nominees) for
the account of Charlotte Barder



23 Feb 05: Sale of 11,000 Futura shares from James Barder and purchase of 11,000
Futura shares into Sippdeal Trustees Ltd for the account of James Barder



26 Feb 07: Sale of 74,500 Futura shares from James Barder and purchase of 74,500
Futura shares into Sippdeal Trustees Ltd for the account of James Barder





David B Davies, Product Development Director

13 July 2005: Sale of 15,152 Futura shares from David Davies and purchase of
15,152 Futura shares into Hargreaves Lansdown Vantage SIPP for the account of
David Davies



26 Mar 07: Sale of 61,084 Futura shares from David Davies and purchase of 60,381
Futura shares into Hargreaves Lansdown Vantage SIPP for the account of David
Davies.  The balance of 703 Futura shares not purchased in to the Hargreaves
Lansdown Vantage SIPP covered dealing costs associated with the transaction.





For further information:

Futura Medical plc
James Barder, Chief Executive                         Tel: [phone]
mail to: [e-mail]             www.futuramedical.co.uk

Buchanan Communications
Mark Court / Rebecca Skye Dietrich                    Tel: [phone]

Canaccord Adams
Mark Ashurst / Tyler Broda                            Tel: + 44 (0) 20 7050 6500





Notes to Editors

Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for
consumer healthcare.  The Company is developing a portfolio of products and its
strategy is to license their manufacture and distribution to major
pharmaceutical and healthcare groups.



Futura is based in Guildford, Surrey, and its shares trade on the AIM market of
the London Stock Exchange.



www.futuramedical.co.uk


                      This information is provided by RNS
            The company news service from the London Stock Exchange